SYS-CON MEDIA Authors: Unitiv Blog, Kevin Benedict, Mark R. Hinkle, Glenn Rossman, Jason Bloomberg

News Feed Item

Investigation Report on China Pemetrexed Market, 2009-2018

 


 

DUBLIN, Mar. 28, 2014 /PRNewswire/ --Research and Markets (http://www.researchandmarkets.com/research/cvsjq3/investigation) has announced the addition of the "Investigation Report on China Pemetrexed Market, 2009-2018" report to their offering.

(Logo: http://photos.prnewswire.com/prnh/20130307/600769)

Pemetrexed, originally developed by Eli Lilly and Company, is a multi-targeted antimetabolite antitumor drug. This product is with huge growth potential in the market.

Approved by FDA in February 2004, pemetrexed is to treat unresectable malignant pleural mesothelioma with cisplatin. It is the first drug approved by FDA to treat the disease. In August 2004 pemetrexed was approved as a second-line drug for local or metastatic non-small cell lung cancer.

So far pemetrexed (brand name ""Alimta"") has been approved to more than 60 countries worldwide. The product has been a best seller of Eli Lilly and Company since it was launched, and its sales value keeps increasing year after year. The CAGR of sales value of pemetrexed was 50.6% from 2004 to 2011. The sales value was only USD 140 million in 2004 and reached USD 460 million in 2005. In 2011, it grew rapidly to USD 2.46 billion.

In the field of antitumor drugs in China, antimetabolic drug is one of the most common types among traditional anti-tumor chemotherapy drugs. Market size of pemetrexed in China has increased rapidly in recent years. The CAGR of its sales value exceeded 70% from 2006 to 2013.

Pemetrexed was approved to clinical use in China in 2004. It was approved to China in 2005 to treat malignant pleural mesothelioma. As a multi-targeted antimetabolite antitumor drug, pemetrexed can treat non-small cell lung cancer, pancreatic cancer and breast cancer with little side effect. Mechanism of pemetrexed is better than traditional antifolate drugs with great competitiveness in the field.

Hansoh Pharmaceutical and Qilu Pharmaceutical were approved to produce APIs and preparation of this drug respectively in 2005 and 2006. Seeing the great future in the market, a large number of manufacturers start to produce the drug. In 2005, many domestic manufacturers began to apply for the production of raw materials and injections. The competition becomes more intense every day.

From 2005 to 2010, Eli Lilly and Company occupied most of Chinese sample hospital market. However, Qilu Pharmaceutical and Hansoh Pharmaceutical has caught up with Eli Lilly and Company since 2011. The main reason is that drugs made within the country seize more market share with relatively low price. As a result, the market is mostly occupied by Qilu Pharmaceutical, Hansoh Pharmaceutical and Eli Lilly and Company.


Key Topics Covered:

1 Relevant Concepts of Pemetrexed

2 Market Overview of Pemetrexed in China, 2009-2013

3 Investigation on Sales Value of Pemetrexed in China, 2009-2013

4 Investigation on Market Share of Major Pemetrexed Manufacturers in China, 2009-2013

5 Investigation on Market Size of Pemetrexed by Dosage Form in China, 2009-2013

6 Reference Price of Pemetrexed Produced by Different Enterprises in China Hospital Market

7 Prospect of China Pemetrexed Market, 2014-2018


Companies Mentioned:

  • Dezhou Pharmaceutical
  • Eli Lilly and Company
  • Hansoh Pharmaceutical
  • Jiangsu Aosaikang Pharmaceutical
  • LILLY France
  • Nanjing Pharmaceutical Factory
  • Nanjing Yadong Qitian Pharmaceutical
  • Qilu Pharmaceutical


For more information visit http://www.researchandmarkets.com/research/cvsjq3/investigation

Media Contact: Laura Wood , +353-1-481-1716, [email protected]


 

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.